Log In
BCIQ
Print this Print this
 

sotagliflozin (SAR439954) (formerly LX4211 tablet)

  Manage Alerts
Collapse Summary General Information
Company Lexicon Pharmaceuticals Inc.
DescriptionDual sodium-glucose cotransporter 1 (SGLT1) and SGLT2 inhibitor
Molecular Target Sodium-glucose cotransporter 1 (SGLT1) ; Sodium-glucose cotransporter 2 (SGLT2)
Mechanism of ActionSodium-glucose cotransporter 2 (SGLT2) inhibitor; Sodium-glucose cotransporter 1 (SGLT1) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationDiabetes
Indication DetailsTreat Type I diabetes; Treat Type II diabetes
Regulatory Designation
PartnerSanofi

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$1,800.0M

$300.0M

$1,400.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

11/06/2015

$1,800.0M

$300.0M

$1,400.0M

07/09/2014

Undisclosed

0

Undisclosed

Get a free BioCentury trial today